Most home devices borrow the clinic's evidence, not its dose.

The randomised, double-blind, sham-device-controlled evidence is unusual for a consumer product. The multicentre HairMax LaserComb trial in men found "a significantly greater increase in mean terminal hair density than subjects in the sham device group (p < 0.0001)" at 26 weeks in 110 completers, with no difference in adverse effects (Leavitt 2009); four further sham-controlled trials of the 7-, 9- and 12-beam combs in 225 evaluable men and women found terminal hair counts up by 18.4–25.7 per cm² against 1.6–9.4 for the sham, "independent of the age and sex of the subject and the lasercomb model" (Jimenez 2014). The 655 nm helmet trials found 35–39% more hair growth than sham in men (Lanzafame 2013) and 37% in women (Lanzafame 2014); a 650 nm laser cap worn every other day for 17 weeks gave a "51% increase in hair counts as compared with sham-treated control patients" in women (Friedman 2017); a Thai helmet trial was superior to sham for density and diameter at 24 weeks, with the authors' own caveats of "small sample size, no long-term follow-up data, and use of inappropriate sham devices" (Suchonwanit 2019).

The meta-analyses: laser therapy in men "superior to placebo (P < .00001)" alongside minoxidil and finasteride (Adil 2017); a pooled effect in both sexes, comb and helmet alike, with a larger effect at lower treatment frequency (Liu 2019); 38 studies and 3,098 patients with standardised mean differences of 1.14 under 20 weeks and 1.44 beyond, and heterogeneity above 80% (Perez 2025); and seven randomised trials in which the device added to minoxidil beat minoxidil alone by 6.6 hairs per cm² with higher satisfaction and no extra adverse events (Mawu 2025). The critical assessment stands: nine trials, small samples, "a lack of visual evidence", no standard regimen and no data on maintenance or long-term consequences (Gupta 2017). Moderate for density in pattern hair loss, as an addition to or alternative to minoxidil — held back from strong because every trial is short, small and paid for by a manufacturer; the hair loss guide grades it the same and ranks it below the drugs, and the red-light guide covers the dose.

The review identified "a total of seven studies: one controlled and six uncontrolled trials. No randomized controlled trials", the best evidence for IPL (three devices) and the least for a home diode laser (one uncontrolled study); "hair reduction percentages ranged from 6% to 72% after repetitive treatments", mostly measured at three and six months, with erythema the most frequent side effect and "oedema, blistering, crusting and pigment changes" also reported (Thaysen-Petersen 2012). The representative trial, in "simulated consumer use", found a 47% mean reduction in terminal hair counts at four weeks and 41% at six months after three weekly treatments, 84% of participants with a significant reduction (mean 51%, range 25–86%) and only mild transient erythema (Emerson 2009). A randomised study of sun exposure after a low-fluence home IPL found no amplified reaction in skin types II–IV and perifollicular darkening in the one type V participant (Thaysen-Petersen 2015).

The physics is the clinic's at lower fluence: melanin in the hair shaft absorbs the light and heats the follicle, so the device needs dark hair on light skin, and the sensors on modern devices refuse to fire on skin too dark to be safe. Grey, white, red and very fine hair do not respond; the face is treated from the cheekbone down, never near the eyes. Moderate for a consistent, measurable, partial and maintainable reduction; the professional-society guideline on these devices sets out the safety case and the gaps (Town 2012), and the laser and IPL guide grades the clinic versions.

The home trial that earns the tier: adults with crow's feet were randomised to a 630 nm LED plus 850 nm infrared mask or a sham mask, five sessions a week for 12 weeks, and followed to week 16; the Crow's Feet Grading Scale scores of independent raters and investigators "showed significant differences at 8, 12, and 16 weeks", the independent raters' improvement rate was 69.2% with "a difference of 49.2% from the control group", and the authors concluded the phototherapy was "effective, safe, well-tolerated, and painless" (Park 2025). It sits on the clinic evidence: the randomised, placebo-controlled, double-blinded split-face trial of 830 and 633 nm LED found wrinkles reduced by up to 36% and elasticity up by up to 19% on the treated side, with "a marked increase in the amount of collagen and elastic fibers" on histology (Lee 2007); the earlier pulsed-LED trial found 90% of subjects improved on digital imaging, 10% on profilometry and a 28% average rise in collagen I density on biopsy (Weiss 2005); and a 2025 sham-controlled trial found glabellar and periorbital wrinkle length reduced against sham with satisfaction of 74–80%, and no advantage to more than two sessions a week (Bragato 2025).

The uncontrolled home studies point the same way and show the limits: men using a 633/830/1072 nm mask for six weeks reported improvement and digital analysis found favourable changes in wrinkles and texture (Mineroff 2023); an under-eye LED device produced "outstanding" satisfaction and a wrinkle-score change from 20.05 to 19.72 that "was not statistically significant" (Wang 2024). Moderate for fine lines and crow's feet, in line with the crow's feet guide; the effect is a softening of texture and fine lines over months, not a change a stranger notices, and it stops accruing when the mask goes in the drawer. The red-light guide covers the wavelengths and doses.

The Korean double-blind randomised trial of a home blue-red LED device found that by week 12 "both inflammatory and noninflammatory acne lesions had decreased significantly, by 77% and 54%, respectively, in the treatment group" with "no significant difference" in the control group, alongside reduced sebum output, smaller sebaceous glands and reduced inflammatory markers on biopsy (Kwon 2013). The home blue-light trial found a significant advantage over placebo for lesion size, lesion erythema and overall skin condition, improvement "as early as post 2 treatments" and a shorter time to resolution (Gold 2011). The over-the-counter 445/630 nm mask trial found a 24.4% reduction in inflammatory lesions against 17.2% for benzoyl peroxide and a 19.0% versus 4.7% improvement on the investigator's global assessment (Nestor 2016).

The 2026 evidence grading put blue and blue-red LED for acne at moderate-quality evidence with favourable safety, red LED alone and light-heat devices at low-quality evidence, and home IPL and heat devices for acne at "not recommended" (Raef 2026); the independent meta-analysis of 14 trials, most of them small, short and at high risk of bias, found no significant difference in lesion counts against non-light treatments (Scott 2019). Emerging for mild to moderate inflammatory acne as an add-on, as the red-light guide grades it; a 24% lesion reduction is real and is also what a well-chosen cleanser achieves, and the treatments that clear acne — topical retinoids, benzoyl peroxide, and prescription therapy — are graded in the retinoids guide. Blue light does nothing for scars or marks.

The home radiofrequency studies share a design: a course of self-treatments, then before-and-after photographs graded by blinded dermatologists, with no untreated or sham group. The handheld multisource phase-controlled device (the technology sold as Newa): 62 completers, no difficulty operating it, and "improvement (downgrade of at least 1 score according to the Fitzpatrick scale) in 91.93%, 96.77%, and 98.39% of study subjects" according to three reviewers after one month of home use, held at one and three months (Shemer 2014). The RF-plus-light periorbital device: 30 completers, "an average reduction of 1.49 Fitzpatrick scores", erythema in all that cleared within an hour and oedema in some that cleared within a day (Gold 2017). The home tripolar device: "an average periorbital wrinkle reduction of 41%" with all patients satisfied (Beilin 2011). The 2024 handheld multi-energy device trial did use a control side and found hydration, elasticity, roughness, pore size and eye-wrinkle volume improved against it at eight weeks, with more collagen I and less MMP-1 in skin samples (Choi 2024).

The home fractional laser: 124 subjects completed a multicentre trial of a 1410 nm non-ablative fractional device, "Fitzpatrick Wrinkle Scale score improvement by one or more grades in 90% of subjects at the completion of the active phase and in 79% of subjects at the completion of the maintenance phase" on blinded review, transient erythema the main side effect, and the authors' stated limitations of "lack of a control group and single-blinded study groups" (Leyden 2012); that device (PaloVia) was withdrawn, and the home lasers now on sale have no sham-controlled trial on PubMed. Emerging for periorbital wrinkles, in line with the laser and IPL guide; the systematic review of clinic radiofrequency finds real but modest tightening at clinic doses (Austin 2022) that the home devices are built not to reach, and no home RF study has measured a jowl or a neck (the sagging skin guide grades that claim limited).

The controlled study: a home device emitting "electrostatic pulses containing RF energy, resulting in high frequency, low level transdermal microcurrent pulsations", tested double-blind against placebo, decreased the eyebrow-to-hairline distance "by 1.338 ± 0.170 cm in the treated eyebrow", significant against both baseline and placebo, in six-minute sessions; the authors called it "a useful tool to delay skin laxity or to prolong the time to the first surgical facial lift" (Nobile 2016). The 2025 focused-electric-field study found, after 14 days, that "the lift height of the upper eyelid and eye corner angle significantly increased", with improvements in drooping lids and eye bags on clinical evaluation, more pronounced at 28 days, and in mice a reversal of age-related muscle-fibre atrophy (Jiang 2025). The 2026 split-face pilot measured muscle: on the stimulated side "OOM thickness significantly increased and the length of fat herniation decreased", the temporal muscle thickened and the temple contour improved, with strong correlations between muscle thickness and the change (Okuda 2026).

Emerging, in line with the sagging skin guide: a brow that sits measurably higher and an orbicularis that holds the fat pad back are plausible, measured, and fade within days of stopping, as muscle tone does. Nothing here treats a hooded lid's excess skin — that is a blepharoplasty question — and the electrical devices are contraindicated with pacemakers and metal implants (Safety).

The JAMA Dermatology research letter is the only measured study of face yoga, and the numbers are worth knowing exactly: 27 women were enrolled, 16 completed 20 weeks of a programme of 30-minute daily exercises for eight weeks and then every other day, and two blinded physicians rated standardised photographs on the Merz-Carruthers scales. Upper cheek fullness improved from 1.1 to 1.8 and lower cheek fullness from 0.9 to 1.6 on the scales (both P = .003), and the raters' estimated age fell from 50.8 to 48.1 years (P = .002); forehead lines, glabellar lines, crow's feet and marionette lines did not change. The authors listed the limitations themselves: "small", "exclusively of middle-aged women", "numerous dropouts", "no control group" (Alam 2018).

Emerging, as the facial volume guide grades it: a mechanism (hypertrophy of the cheek muscles under thinning fat) that fits the one feature that changed, in a study with no control arm and a 41% dropout rate. For crow's feet and forehead lines it did nothing, which is what the crow's feet guide reports. It costs nothing but time, and the time is the reason most people stop.

Cooling the eyelids constricts the dermal and periorbital vessels and reduces fluid in the loose tissue under the eye for an hour or two; the physiology is not disputed and no trial has bothered to measure it on a face, which is why the eye bags guide grades it emerging on the oedema literature — where the review of oedema management finds cooling universally used and unproven for any lasting change (King 2017). The roller study, in 14 subjects, found short-term facial massage "significantly increased facial skin blood flow solely in the right cheek for at least 10 min" and five weeks of daily use improved the vasodilatation response to heat (Miyaji 2018) — a change in vessel reactivity, not in a bag.

Emerging for a morning of less puffiness; nothing for a fat pad, a tear trough or the skin laxity of a true eye bag, which the eye bags guide sorts out. A cold spoon from the fridge does what the €40 roller does.

The review of hand-held home laser and light devices found the data concentrated on hair removal and acne and "a paucity of randomized, double-blind controlled trials" for the rest (Hession 2015); the professional guideline on home IPL notes the devices were being sold for "photo-rejuvenation" without standards or evidence (Town 2012), and the systematic review lists "pigment changes" among their adverse effects (Thaysen-Petersen 2012). The one home LED study to mention pigment reported favourable "UV spots" and "brown spots" numbers from photographic software in an uncontrolled six-week study of men (Mineroff 2023), which is not a pigment outcome.

Limited, and the direction of harm matters: heat and light darken melasma, and a home IPL used on a tanned or darker skin produces the pigment change it was bought to remove. Sun spots respond to clinic IPL, Q-switched and picosecond lasers and to hydroquinone, retinoids and azelaic acid; melasma to tranexamic acid and the triple cream — all graded in the dark spots guide. The device to buy for pigment is a tube of SPF 50.

The home body-RF study is the only measured result: ex-vivo skin showed an 82% rise in hypodermal glycerol release and a 31% rise in collagen synthesis, and in the clinical arm "a significant average reduction of 2.4 cm was measured on the treated thighs" while "on the control thighs a lesser, non-significant reduction was found"; abdominal laxity fell from 1.4 to 0.8 and the abdominal circumference change was not significant, for what the authors called "discrete circumference reduction and moderate laxity improvement" (Boisnic 2010). The clinic version of the same technology increased dermal thickness by 49% on biopsy in a small study (Kaplan 2009).

Limited for cellulite, because a centimetre off a thigh circumference is fluid and fat, not a released fibrous band, and no home device has measured the dimples that define the condition; the cellulite guide grades the brushes, rollers and vibration devices limited and sets out what does move a dimple (subcision, and the clinic energy devices with their own caveats). The upper arms guide covers the body laxity claims.

Look at what each trial measured. The home RF studies graded periorbital and perioral wrinkles (Beilin 2011; Gold 2017; Shemer 2014); the microcurrent and stimulation studies measured brows, lids and temples (Nobile 2016; Okuda 2026); the randomised comparison of gua sha and a facial roller found "reductions ranging from 2.23 to 2.40 mm in the gua sha group" and "2.75–3.26 mm in the facial roller group" in facial-contour measurements, gua sha lowering muscle tone and the roller improving elasticity readings, in a trial that compared the two tools with each other and not with doing nothing (Ahn 2025). Millimetres of contour after massage are lymph and fluid; a jowl is fat and ligament descent, graded in the jowls guide.

Limited. The clinic devices that measurably tighten the lower face — microfocused ultrasound, monopolar and microneedle radiofrequency — are graded moderate in the sagging skin guide at doses no consumer device may deliver, and the "home HIFU" machines on the marketplaces are either too weak to do anything or, if they are not, an unsupervised way to burn the fat and nerves of the face (Safety). The neck guide has the same verdict for the neck.